News
Avacta to Launch SARS-CoV-2 ELISA Laboratory Test
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Enzyme linked...
News
Vibalogics appoints global CEO to lead U.S. expansion
Vibalogics, a global contract development and manufacturing organization (CDMO) that specializes in the production of virotherapy products, has announced the appointment of Tom Hochuli as Chief Executive Officer as the company accelerates its U.S. expansion and global growth strategy.
Bringing...
News
Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine
Intravacc, a global provider of translational research and development of viral and bacterial vaccines, has been awarded a contract with base and options that may total $9.4 million from the U.S. National Institute of Allergy and Infectious Diseases (NIAID),...
News
Cipla Health ventures into antifungal product category with launch of Clocip
Cipla Health Ltd., a leading consumer healthcare brand, has forayed into the antifungal product category with the introduction of Clocip, to offer a hardworking skin infection solution for hardworking people enabling them to continue work without any discomfort.
Available in...
News
Roche announces FDA approval of Gavreto for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
Roche announced that the United States (US) FDA has approved Gavreto™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was...
Clinical Trials
Merck announces positive results phase 3 trials of gefapixant 45 mg twice daily in patients with refractory or unexplained chronic cough
Merck, known as MSD outside the United States and Canada, has announced the results from two pivotal phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist,...
News
Mylan to Acquire Aspen’s Thrombosis Business in Europe
Mylan N.V. announced an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited's thrombosis business in Europe for EUR 641.9 million, subject to customary closing conditions and European regulatory
clearances. The transaction is expected...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
